JesÃºs RodrÃ-guez-BaÃ±o

List of Publications by Year
in descending order

398 papers	24,466 citations	9786 73 h-index	11052 137 g-index
453 all docs	453 docs citations	453 times ranked	23493 citing authors

#	Article	IF	Citations
1	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	9.1	3,672
2	The global threat of antimicrobial resistance: science for intervention. New Microbes and New Infections, 2015, 6, 22-29.	1.6	811
3	ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clinical Microbiology and Infection, 2014, 20, 1-55.	6.0	640
4	Global dissemination of a multidrug resistant Escherichia coli clone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5694-5699.	7.1	498
5	Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clinical Microbiology Reviews, 2018, 31, .	13.6	486
6	A Multinational Survey of Risk Factors for Infection with Extendedâ€Spectrum Î²â€Lactamaseâ€“Producing Enterobacteriaceae in Nonhospitalized Patients. Clinical Infectious Diseases, 2009, 49, 682-690.	5.8	415
7	Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients. Journal of Clinical Microbiology, 2004, 42, 1089-1094.	3.9	395
8	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
9	Community Infections Caused by Extended-Spectrum Î²-Lactamaseâ€“Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897.	3.8	333
10	Â-Lactam/Â-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum Â-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts. Clinical Infectious Diseases, 2012, 54, 167-174.	5.8	329
11	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq1 1 0.784314 rgBT /Overlo	8.4	324
12	Communityâ€Onset Bacteremia Due to Extendedâ€Spectrum Î²â€Lactamaseâ€“ProducingEscherichia coli:Risk Factors and Prognosis. Clinical Infectious Diseases, 2010, 50, 40-48.	5.8	294
13	Bacteremia Due to Extended-Spectrum Â-Lactamase-Producing Escherichia coli in the CTX-M Era: A New Clinical Challenge. Clinical Infectious Diseases, 2006, 43, 1407-1414.	5.8	251
14	Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clinical Microbiology and Infection, 2020, 26, 1525-1536.	6.0	249
15	Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clinical Microbiology and Infection, 2002, 8, 687-693.	6.0	246
16	Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clinical Microbiology and Infection, 2014, 20, O245-O254.	6.0	241
17	Surveillance for control of antimicrobial resistance. Lancet Infectious Diseases, The, 2018, 18, e99-e106.	9.1	235
18	Escherichia coli: an old friend with new tidings. FEMS Microbiology Reviews, 2016, 40, 437-463.	8.6	225

#	Article	IF	Citations
19	Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies. Journal of Infection, 2014, 68, 242-251.	3.3	207
20	Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clinical Microbiology and Infection, 2008, 14, 276-278.	6.0	196
21	Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology, 2007, 46, 622-630.	7.3	192
22	Impact of an Evidence-Based Bundle Intervention in the Quality-of-Care Management and Outcome of Staphylococcus aureus Bacteremia. Clinical Infectious Diseases, 2013, 57, 1225-1233.	5.8	192
23	Faecal carriage of extended-spectrum Â-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. Journal of Antimicrobial Chemotherapy, 2008, 62, 1142-1149.	3.0	190
24	Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrobial Resistance and Infection Control, 2017, 6, 113.	4.1	186
25	Impact of Inadequate Empirical Therapy on the Mortality of Patients with Bloodstream Infections: a Propensity Score-Based Analysis. Antimicrobial Agents and Chemotherapy, 2012, 56, 472-478.	3.2	182
26	Contribution of Efflux Pumps, Porins, and Î²-Lactamases to Multidrug Resistance in Clinical Isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2013, 57, 5247-5257.	3.2	170
27	Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine, 2019, 45, 172-189.	8.2	155
28	Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548.	5.8	153
29	The Use of Noncarbapenem Î²-Lactams for the Treatment of Extended-Spectrum Î²-Lactamase Infections. Clinical Infectious Diseases, 2017, 64, 972-980.	5.8	145
30	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli. Journal of Clinical Microbiology, 2010, 48, 1726-1731.	3.9	144
31	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
32	Clinical significance of extended-spectrum Î²-lactamases. Expert Review of Anti-Infective Therapy, 2008, 6, 671-683.	4.4	136
33	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, 2013, 57, 208-216.	5.8	135
34	Clinical and Molecular Epidemiology of Extended-Spectrum Î² -Lactamaseâ€"Producing Escherichia coli as a Cause of Nosocomial Infection or Colonization: Implications for Control. Clinical Infectious Diseases, 2006, 42, 37-45.	5.8	133
35	Extended-spectrum and CMY-type b-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clinical Microbiology and Infection, 2010, 16, 33-38.	6.0	133
36	Clinical Features and Epidemiology ofAcinetobacter baumanniiColonization and Infection in Spanish Hospitals. Infection Control and Hospital Epidemiology, 2004, 25, 819-824.	1.8	130

#	Article	IF	Citations
37	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High In Vitro Susceptibility to Colistin and Meropenem. Antimicrobial Agents and Chemotherapy, 2015, 59, 3406-3412.	3.2	130
38	Current Epidemiology and Outcome of Infective Endocarditis. Medicine (United States), 2015, 94, e1816.	1.0	129
39	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 1265-1272.	3.2	123
40	Intravenous fosfomycinâ€"back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection, 2017, 23, 363-372.	6.0	119
41	National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 2011-2021.	3.0	117
42	ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. Clinical Microbiology and Infection, 2019, 25, 807-817.	6.0	114
43	Prevalence of plasmid-mediated quinolone resistance determinants qnr and aac(6â€²)-Ib-cr in Escherichia coli and Klebsiella pneumoniae producing extended-spectrum Î²-lactamases in Spain. International Journal of Antimicrobial Agents, 2012, 39, 431-434.	2.5	107
44	Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum-Â-lactamase-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2013, 68, 68-73.	3.0	106
45	Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo-Î²-lactamase-producing Klebsiella oxytoca. Clinical Microbiology and Infection, 2013, 19, E490-E498.	6.0	104
46	Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clinical Microbiology and Infection, 2013, 19, 962-968.	6.0	104
47	Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis. Clinical Infectious Diseases, 2014, 58, 1413-1421.	5.8	104
48	Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors. Quality of Life Research, 2005, 14, 1301-1310.	3.1	103
49	ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clinical Microbiology and Infection, 2022, 28, 222-238.	6.0	103
50	Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clinical Microbiology and Infection, 2005, 11, 874-879.	6.0	102
51	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	8.2	101
52	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
53	Risk-factors for emerging bloodstream infections caused by extended-spectrum Î²-lactamase-producing Escherichia coli. Clinical Microbiology and Infection, 2008, 14, 180-183.	6.0	95
54	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection, 2021, 27, 244-252.	6.0	95

#	Article	IF	Citations
55	Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clinical Microbiology and Infection, 2011, 17, 738-746.	6.0	93
56	Prevalence and molecular epidemiology of acquired AmpC Î²-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 253-259.	2.9	91
57	Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2015, 70, 905-913.	3.0	91
58	Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli. Antimicrobial Agents and Chemotherapy, 2013, 57, 3402-3404.	3.2	90
59	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
60	Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi50-vi58.	3.0	89
61	Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive â€œbundleâ€•approach. American Journal of Infection Control, 2009, 37, 715-722.	2.3	88
62	Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clinical Microbiology and Infection, 2010, 16, 1408-1413.	6.0	87
63	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 5602-5610.	3.2	87
64	Diversity of Escherichia coli Strains Producing Extended-Spectrum Î²-Lactamases in Spain: Second Nationwide Study. Journal of Clinical Microbiology, 2010, 48, 2840-2845.	3.9	86
65	Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. Clinical Microbiology and Infection, 2018, 24, 577-590.	6.0	85
66	Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Research Notes, 2011, 4, 5.	1.4	84
67	Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. Journal of Antimicrobial Chemotherapy, 2014, 69, 3119-3126.	3.0	81
68	Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemaseâ€“Producing K. pneumoniae: Validation of Scores and Proposal for Management. Clinical Infectious Diseases, 2018, 66, 1204-1210.	5.8	81
69	Increased raw poultry meat colonization by extended spectrum beta-lactamase-producing Escherichia coli in the south of Spain. International Journal of Food Microbiology, 2012, 159, 69-73.	4.7	79
70	Four Main Virotypes among Extended-Spectrum-Î²-Lactamase-Producing Isolates of Escherichia coli O25b:H4-B2-ST131: Bacterial, Epidemiological, and Clinical Characteristics. Journal of Clinical Microbiology, 2013, 51, 3358-3367.	3.9	76
71	Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2014, 69, 3203-3215.	3.0	76
72	Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clinical Microbiology and Infection, 2019, 25, 932-942.	6.0	74

#	Article	IF	Citations
73	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. Journal of Infection, 2016, 72, 152-160.	3.3	73
74	Clinical Epidemiology of Stenotrophomonas maltophilia Colonization and Infection. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	72
75	Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1122-1129.	1.8	72
76	Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum Î²-lactamase-producing and extended-spectrum Î²-lactamase-non-producing Escherichia coli isolates.. Clinical Microbiology and Infection, 2010, 16, 132-136.	6.0	71
77	Prognostic factors in left-sided endocarditis: results from the andalusian multicenter cohort. BMC Infectious Diseases, 2010, 10, 17.	2.9	70
78	Epidemiology and Clinical Features of Community-Acquired, Healthcare Associated and Nosocomial Bloodstream Infections in Tertiary and Community Hospitals. Clinical Microbiology and Infection, 2009, 16, 1408-13.	6.0	68
79	Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clinical Microbiology and Infection, 2013, 19, 1049-1057.	6.0	67
80	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical Microbiology and Infection, 2018, 24, 546.e1-546.e8.	6.0	67
81	Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clinical Microbiology and Infection, 2021, 27, 228-235.	6.0	67
82	A Change in the Epidemiology of Infections Due to Extended-Spectrum Â-Lactamase–Producing Organisms. Clinical Infectious Diseases, 2006, 42, 935-937.	5.8	65
83	Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps. Journal of Antimicrobial Chemotherapy, 2015, 70, 3222-3229.	3.0	65
84	Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. Journal of Infection, 2011, 62, 193-199.	3.3	64
85	Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum Î²-lactamases. Clinical Microbiology and Infection, 2005, 11, 625-631.	6.0	62
86	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 783-792.	9.1	62
87	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clinical Microbiology and Infection, 2022, 28, 550-557.	6.0	62
88	Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum Â-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open, 2015, 5, e007363-e007363.	1.9	61
89	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax, 2021, 76, 920-929.	5.6	60
90	Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	59

#	Article	IF	Citations
91	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	6.0	58
92	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clinical Microbiology and Infection, 2018, 24, 1070-1076.	6.0	58
93	A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance. Nature Microbiology, 2019, 4, 1160-1172.	13.3	58
94	Timing of Oseltamivir Administration and Outcomes in Hospitalized Adults With Pandemic 2009 Influenza A(H1N1) Virus Infection. Chest, 2011, 140, 1025-1032.	0.8	57
95	Knowledge and perceptions of junior and senior Spanish resident doctors about antibiotic use and resistance: Results of a multicenter survey. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 199-204.	0.5	57
96	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clinical Microbiology and Infection, 2015, 21, 491.e1-491.e10.	6.0	57
97	Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells byin vitroactivation andin vivoin HIV-infected patients. Clinical and Experimental Immunology, 2002, 129, 119-124.	2.6	56
98	Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. Journal of Antimicrobial Chemotherapy, 2014, 69, 568-571.	3.0	56
99	Genotypic identification of an undescribed spotted fever group rickettsia in Ixodes ricinus from southwestern Spain.. American Journal of Tropical Medicine and Hygiene, 1998, 58, 570-577.	1.4	56
100	Patient engagement with surgical site infection prevention: an expert panel perspective. Antimicrobial Resistance and Infection Control, 2017, 6, 45.	4.1	55
101	Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme. PLoS ONE, 2017, 12, e0174454.	2.5	54
102	Epidemiologic and Clinical Impact of Acinetobacter baumannii Colonization and Infection. Medicine (United States), 2014, 93, 202-210.	1.0	53
103	Combatting resistance in intensive care: the multimodal approach of the Spanish ICU â€œZero Resistanceâ€• program. Critical Care, 2015, 19, 114.	5.8	53
104	Extended-spectrum Î²-lactamases in ambulatory care: a clinical perspective. Clinical Microbiology and Infection, 2008, 14, 104-110.	6.0	52
105	Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. Journal of Antimicrobial Chemotherapy, 2014, 69, 809-814.	3.0	52
106	Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum Î²-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 2109-2113.	3.2	51
107	The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. Clinical Microbiology and Infection, 2019, 25, 555-561.	6.0	51
108	Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. Journal of Infection, 2009, 58, 131-137.	3.3	50

#	Article	IF	Citations
109	Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Therapeutic Advances in Infectious Disease, 2013, 1, 49-69.	1.8	50
110	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2012, 56, 3576-3581.	3.2	49
111	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49
112	Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: An observational cohort study. Medicina ClÃnica, 2012, 139, 185-191.	0.6	48
113	Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. Journal of Infection, 2018, 77, 516-525.	3.3	48
114	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardshipâ€"results from an international cross-sectional survey. World Journal of Emergency Surgery, 2017, 12, 34.	5.0	47
115	Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Review of Anticancer Therapy, 2006, 6, 671-678.	2.4	46
116	Characterisation of the first ongoing outbreak due to KPC-3-producing Klebsiella pneumoniae (ST512) in Spain. International Journal of Antimicrobial Agents, 2014, 44, 538-540.	2.5	46
117	CTX-M-15-H30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producingEscherichia colibacteraemia of urinary origin in Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2125-2130.	3.0	46
118	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
119	Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients. Clinical and Experimental Immunology, 2003, 134, 464-469.	2.6	45
120	Clinical Features and Molecular Epidemiology of CMYâ€Type Î²â€Lactamaseâ€"ProducingEscherichia coli. Clinical Infectious Diseases, 2009, 48, 739-744.	5.8	45
121	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC Î²-lactamases. Journal of Infection, 2012, 64, 176-183.	3.3	45
122	Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum Î²-lactamase belonging to ST410 phylogroup A. International Journal of Antimicrobial Agents, 2011, 37, 365-367.	2.5	44
123	Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. Clinical Microbiology and Infection, 2012, 18, E55-E62.	6.0	44
124	Successful multifaceted intervention aimed to reduce short peripheral venous catheter-related adverse events: A quasiexperimental cohort study. American Journal of Infection Control, 2013, 41, 520-526.	2.3	44
125	Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 1423-1430.	3.0	44
126	European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. Clinical Microbiology and Infection, 2015, 21, 354-361.	6.0	44

#	Article	IF	Citations
127	Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system*. Journal of Antimicrobial Chemotherapy, 2014, 69, 2629-2633.	3.0	43
128	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
129	Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi30-vi39.	3.0	43
130	Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials, 2015, 16, 450.	1.6	42
131	Overproduction of outer membrane protein A (OmpA) by Acinetobacter baumannii is a risk factor for nosocomial pneumonia, bacteremia and mortality increase.. Journal of Infectious Diseases, 2017, 215, jix010.	4.0	42
132	ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus. Clinical Microbiology and Infection, 2019, 25, 13-19.	6.0	42
133	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
134	Efficacy of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	41
135	Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. Clinical Microbiology and Infection, 2017, 23, 49.e1-49.e8.	6.0	41
136	Response to Bile Salts in Clinical Strains of Acinetobacter baumannii Lacking the AdeABC Efflux Pump: Virulence Associated with Quorum Sensing. Frontiers in Cellular and Infection Microbiology, 2017, 7, 143.	3.9	40
137	Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosisâ€”The ESCAPE Study. Clinical Infectious Diseases, 2018, 66, 825-832.	5.8	40
138	The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information. Clinical Microbiology and Infection, 2018, 24, 105-109.	6.0	40
139	ESCMIDâ€”an international Europe-based society committed to fostering cross-border collaboration and education to improve patient care. Clinical Microbiology and Infection, 2018, 24, 1-2.	6.0	40
140	Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group. Clinical Infectious Diseases, 2018, 68, 29-36.	5.8	40
141	Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. Journal of Infection, 2015, 71, 385-394.	3.3	39
142	Staffing for infectious diseases, clinical microbiology and infection control in hospitals in 2015: results of an ESCMID member survey. Clinical Microbiology and Infection, 2016, 22, 812.e9-812.e17.	6.0	39
143	â€œThe 3/3 Strategyâ€• A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology. PLoS ONE, 2012, 7, e47200.	2.5	39
144	Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. Scientific Reports, 2021, 11, 23380.	3.3	39

#	Article	IF	Citations
145	Reply to Tarchini. Clinical Infectious Diseases, 2010, 51, 120-121.	5.8	38
146	Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. Aids, 2010, 24, 2461-2467.	2.2	38
147	Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open, 2015, 5, e006723-e006723.	1.9	38
148	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. Clinical Microbiology and Infection, 2017, 23, 325-331.	6.0	38
149	Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococcus aureus in Spain. Clinical Microbiology and Infection, 2009, 15, 1111-1118.	6.0	37
150	Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum Î²-lactamase-producing Escherichia coli. Clinical Microbiology and Infection, 2012, 18, 894-900.	6.0	36
151	Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2016, 71, 3242-3249.	3.0	36
152	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585.	2.5	36
153	Virulence Profiles of Bacteremic Extended-Spectrum Î²-Lactamase-Producing Escherichia coli: Association with Epidemiological and Clinical Features. PLoS ONE, 2012, 7, e44238.	2.5	35
154	Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 626-632.	0.5	34
155	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity scoreâ€“derived analysis of a population-based, multicentre prospective cohort. Clinical Microbiology and Infection, 2016, 22, 733.e1-733.e8.	6.0	34
156	Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. BMJ Open, 2018, 8, e020251.	1.9	34
157	Influence of Early Surgical Treatment on the Prognosis of Left-Sided Infective Endocarditis: A Multicenter Cohort Study. Mayo Clinic Proceedings, 2014, 89, 1397-1405.	3.0	33
158	Combined Use of the Ab105-2Ï†Î”CI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. Microorganisms, 2019, 7, 556.	3.6	33
159	Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847.	2.5	33
160	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	33
161	Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1057-1065.	6.0	33
162	Pneumonia Complicating Pandemic (H1N1) 2009. Medicine (United States), 2011, 90, 328-336.	1.0	32

#	Article	IF	Citations
163	Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 625.e1-625.e23.	0.5	32
164	Long-Term Control of Endemic Hospital-Wide Methicillin-ResistantStaphylococcus aureus(MRSA): The Impact of Targeted Active Surveillance for MRSA in Patients and Healthcare Workers. Infection Control and Hospital Epidemiology, 2010, 31, 786-795.	1.8	31
165	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 547-556.	2.9	31
166	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
167	Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: Results of an online survey. International Journal of Antimicrobial Agents, 2019, 54, 478-486.	2.5	31
168	Type 1 Integrons in Epidemiologically Unrelated Acinetobacter baumannii Isolates Collected at Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2004, 48, 364-365.	3.2	30
169	Eradication of an extensive outbreak in a neonatal unit caused by two sequential Klebsiella pneumoniae clones harbouring related plasmids encoding an extended-spectrum Î²-lactamase. Journal of Hospital Infection, 2009, 73, 157-163.	2.9	30
170	Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis. Clinical Microbiology and Infection, 2020, 26, 358-365.	6.0	30
171	Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu. Journal of Antimicrobial Chemotherapy, 2013, 68, 1609-1615.	3.0	29
172	Effects of isolation on patients and staff. American Journal of Infection Control, 2015, 43, 397-399.	2.3	29
173	Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 337.e1-337.e21.	0.5	29
174	Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study. Clinical Microbiology and Infection, 2017, 23, 27-32.	6.0	29
175	Molecular insights into fosfomycin resistance inEscherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw573.	3.0	29
176	Extended Infusion of Î²-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	5.8	29
177	Effect of Statin Therapy in the Outcome of Bloodstream Infections Due to Staphylococcus aureus: A Prospective Cohort Study. PLoS ONE, 2013, 8, e82958.	2.5	28
178	Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections. JAMA Network Open, 2022, 5, e2137277.	5.9	28
179	Current management of bloodstream infections. Expert Review of Anti-Infective Therapy, 2010, 8, 815-829.	4.4	27
180	Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. Journal of Global Antimicrobial Resistance, 2021, 25, 5-7.	2.2	27

#	Article	IF	Citations
181	Are hip hemiarthroplasty and total hip arthroplasty infections different entities? The importance of hip fractures. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1439-1448.	2.9	26
182	Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum Î²-Lactamases Collected in Two Multicenter Studies in Spain. Microbial Drug Resistance, 2018, 24, 367-376.	2.0	26
183	Klebsiella pneumoniae Strains Producing Extended-Spectrum Î²-Lactamases in Spain: Microbiological and Clinical Features. Journal of Clinical Microbiology, 2011, 49, 1134-1136.	3.9	25
184	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. Journal of Infection, 2013, 67, 185-193.	3.3	25
185	Predictors of early mortality in very elderly patients with bacteremia: a prospective multicenter cohort. International Journal of Infectious Diseases, 2014, 26, 83-87.	3.3	25
186	Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. Clinical Microbiology and Infection, 2017, 23, 672.e1-672.e11.	6.0	25
187	Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe. BMJ Open, 2019, 9, e027683.	1.9	25
188	Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784.	3.0	24
189	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280.	5.8	24
190	Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut, 2009, 58, 1654-1660.	12.1	23
191	Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2012, 39, 472-477.	2.5	23
192	First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006in Spain. Antimicrobial Agents and Chemotherapy, 2013, 57, 589-591.	3.2	23
193	Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 338-341.	0.5	23
194	Lessons from an outbreak of metallo-Î²-lactamase-producing Klebsiella oxytoca in an intensive care unit: the importance of time at risk and combination therapy. Journal of Hospital Infection, 2015, 89, 123-131.	2.9	23
195	Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 551-558.	0.5	23
196	Outcome of bacteraemia due to extended-spectrum Î²-lactamase-producing Escherichia coli: Impact of microbiological determinants. Journal of Infection, 2013, 67, 27-34.	3.3	22
197	Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 385-388.	0.5	22
198	EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study. BMJ Open, 2017, 7, e015365.	1.9	22

#	Article	IF	Citations
199	Selection of empiric therapy in patients with catheter-related infections. Clinical Microbiology and Infection, 2002, 8, 275-281.	6.0	21
200	Genetic Variability among ampC Genes from Acinetobacter Genomic Species 3. Antimicrobial Agents and Chemotherapy, 2009, 53, 1177-1184.	3.2	21
201	Assessment of the presence of extended-spectrum beta-lactamase-producing Escherichia coli in eggshells and ready-to-eat products. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1045-1047.	2.9	21
202	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. Journal of Antimicrobial Chemotherapy, 2016, 71, 521-530.	3.0	21
203	Direct bacterial identification from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry: A systematic review and meta-analysis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 484-492.	0.5	21
204	Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clinical Microbiology and Infection, 2019, 25, 964-970.	6.0	21
205	The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection . Infection and Drug Resistance, 2019, Volume 12, 329-343.	2.7	21
206	Vagino-rectal colonization and maternalâ€“neonatal transmission of Enterobacteriaceae producing extended-spectrum Î²-lactamases or carbapenemases: a cross-sectional study. Journal of Hospital Infection, 2019, 101, 167-174.	2.9	21
207	Guidance on reporting multivariable regression models in CMI. Clinical Microbiology and Infection, 2020, 26, 1-2.	6.0	21
208	Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics. Nature Communications, 2021, 12, 2240.	12.8	21
209	Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. International Journal of Antimicrobial Agents, 2021, 57, 106345.	2.5	21
210	Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy. Therapeutic Drug Monitoring, 2007, 29, 171-176.	2.0	21
211	Minimum requirements in infection control. Clinical Microbiology and Infection, 2015, 21, 1072-1076.	6.0	20
212	Epidemiology and prognosis of candidaemia in elderly patients. Mycoses, 2017, 60, 808-817.	4.0	20
213	Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clinic Proceedings, 2017, 92, 1469-1478.	3.0	20
214	Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections. JAMA - Journal of the American Medical Association, 2019, 321, 612.	7.4	20
215	Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?. Journal of Antimicrobial Chemotherapy, 2015, 70, 2652-2660.	3.0	19
216	Prevalence and transmission dynamics of Escherichia coli ST131 among contacts of infected community and hospitalized patients. Clinical Microbiology and Infection, 2018, 24, 618-623.	6.0	19

#	Article	IF	Citations
217	Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2172-2181.	3.0	19
218	Comment on: Redefining extended-spectrum Â-lactamases: balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 2009, 64, 212-213.	3.0	18
219	No differences in quality of life between men and women undergoing HIV antiretroviral treatment. Impact of demographic, clinical and psychosocial factors. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 943-952.	1.2	18
220	Prevalence of and Risk Factors for Biliary Carriage of Bacteria Showing Worrisome and Unexpected Resistance Traits. Journal of Clinical Microbiology, 2013, 51, 518-521.	3.9	18
221	Amoxicillin dosing recommendations are very different in European countries: aÂcross-sectional survey. Clinical Microbiology and Infection, 2017, 23, 414-415.	6.0	18
222	Population pharmacokinetics and pharmacodynamics of fosfomycin in nonâ€“critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clinical Microbiology and Infection, 2018, 24, 1177-1183.	6.0	18
223	The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia. Journal of Infection, 2018, 77, 9-17.	3.3	18
224	The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection. Journal of Infection, 2018, 76, 121-131.	3.3	18
225	Intestinal colonization due to Escherichia coli ST131: risk factors and prevalence. Antimicrobial Resistance and Infection Control, 2018, 7, 135.	4.1	18
226	Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality inStaphylococcus aureusbacteraemia. Journal of Antimicrobial Chemotherapy, 2019, 74, 1101-1107.	3.0	18
227	Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. Clinical Infectious Diseases, 2019, 69, 956-962.	5.8	18
228	CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. JAC-Antimicrobial Resistance, 2021, 3, dlaa112.	2.1	18
229	Systemic Paradoxical Response to Antituberculous Drugs: Resolution with Corticosteroid Therapy. Clinical Infectious Diseases, 1997, 24, 517-519.	5.8	17
230	Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and Î²-Lactams in Acinetobacter Genospecies 3. Antimicrobial Agents and Chemotherapy, 2004, 48, 1430-1432.	3.2	17
231	Analysis of plasmids encoding extended-spectrum Î²-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville. International Journal of Antimicrobial Agents, 2007, 29, 89-92.	2.5	17
232	Within-lineage variability of ST131 Escherichia coli isolates from humans and companion animals in the south of Europe. Journal of Antimicrobial Chemotherapy, 2014, 69, 271-273.	3.0	17
233	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. Journal of Infection, 2015, 70, 247-254.	3.3	17
234	MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw562.	3.0	17

#	Article	IF	Citations
235	Social media posts and online search behaviour as early-warning system for MRSA outbreaks. Antimicrobial Resistance and Infection Control, 2018, 7, 69.	4.1	17
236	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	4.7	17
237	Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark. Journal of Antimicrobial Chemotherapy, 2020, 75, 3656-3664.	3.0	17
238	Azithromycin uptake by tissue cultured epithelial cells. Journal of Antimicrobial Chemotherapy, 1997, 39, 293-295.	3.0	16
239	Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. Journal of Antimicrobial Chemotherapy, 2010, 65, 1071-1073.	3.0	16
240	The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study. Clinical Microbiology and Infection, 2018, 24, 180-184.	6.0	16
241	Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched caseâ€“control study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 51-56.	2.9	16
242	Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae. Frontiers in Microbiology, 2018, 9, 912.	3.5	16
243	Clinical characteristics and outcome of bacteraemia caused by Enterobacter cloacae and Klebsiella aerogenes: more similarities than differences. Journal of Global Antimicrobial Resistance, 2021, 25, 351-358.	2.2	16
244	Clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus causing bacteraemia in Southern Spain. Journal of Hospital Infection, 2012, 81, 257-263.	2.9	15
245	Bacteraemia due to non-ESBL-producing Escherichia coli O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes. International Journal of Antimicrobial Agents, 2017, 49, 498-502.	2.5	15
246	Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum Î²-lactamase (ESBL) or AmpC Î²-lactamase: A propensity score study. International Journal of Antimicrobial Agents, 2019, 54, 189-196.	2.5	15
247	A prospective, multicenter case control study of risk factors for acquisition and mortality in Enterobacter species bacteremia. Journal of Infection, 2020, 80, 174-181.	3.3	15
248	Epidemiologic changes in bloodstream infections in AndalucÃa (Spain) during the last decade. Clinical Microbiology and Infection, 2021, 27, 283.e9-283.e16.	6.0	15
249	Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales espaÃ±oles. Estudio multicÃ©ntrico nacional: proyecto GEIH-Ab 2000. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 267-271.	0.5	15
250	Analysis of quality antimicrobial agent use in the emergency department of a tertiary care hospital. Emergencias, 2018, 30, 297-302.	0.6	15
251	Salmonella dublin infection: a rare cause of spontaneous bacterial peritonitis and chronic colitis in alcoholic liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2001, 13, 587-589.	1.6	14
252	Neonatal sepsis caused by a CTX-M-32-producing Escherichia coli isolate. Journal of Medical Microbiology, 2008, 57, 1303-1305.	1.8	14

#	Article	IF	Citations
253	Epidemiological and clinical features associated with colonisation/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems. International Journal of Antimicrobial Agents, 2012, 40, 235-238.	2.5	14
254	Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant Staphylococcus aureus bacteraemia from 21 Spanish hospitals. Clinical Microbiology and Infection, 2014, 20, 361-367.	6.0	14
255	World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance. Medicina Intensiva, 2015, 39, 34-39.	0.7	14
256	Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-Â-lactamase-producing Klebsiella oxytoca. Journal of Antimicrobial Chemotherapy, 2015, 70, 313-315.	3.0	14
257	Left-sided infective endocarditis in patients with liver cirrhosis. Journal of Infection, 2015, 71, 627-641.	3.3	14
258	Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii. Frontiers in Microbiology, 2018, 9, 3105.	3.5	14
259	Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open, 2020, 10, e039951.	1.9	14
260	Household acquisition and transmission of extended-spectrum Î²-lactamase (ESBL) -producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. Clinical Microbiology and Infection, 2021, 27, 1322-1329.	6.0	14
261	Hospital infection control in Spain. Journal of Hospital Infection, 2001, 48, 258-260.	2.9	13
262	Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant Escherichia coli. Journal of Clinical Microbiology, 2013, 51, 2414-2417.	3.9	13
263	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. Viral Immunology, 2021, 34, 639-645.	1.3	13
264	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. Microorganisms, 2022, 10, 1021.	3.6	13
265	Clinical Features of Infections and Colonization by Acinetobacter Genospecies 3. Journal of Clinical Microbiology, 2010, 48, 4623-4626.	3.9	12
266	Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infectious Diseases, 2013, 13, 344.	2.9	12
267	Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. Journal of Infection, 2019, 79, 245-252.	3.3	12
268	Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30â€‰day mortality in a multicentre prospective cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 3056-3061.	3.0	12
269	Kawasaki disease and parvovirus B19 infection in an adult HIV-1-infected patient. Clinical Microbiology and Infection, 1998, 4, 609-610.	6.0	11
270	The Times They Are a-Changin': Carbapenems for Extended-Spectrum-Î²-Lactamase-Producing Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 5095-5096.	3.2	11

#	Article	IF	Citations
271	Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 2916-2918.	3.0	11
272	Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres. Epidemiology and Infection, 2016, 144, 1974-1982.	2.1	11
273	Clinical characteristics, treatment and outcomes of MRSA bacteraemia in the elderly. Journal of Infection, 2016, 72, 309-316.	3.3	11
274	High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2102-2109.	3.0	11
275	Predictive value of the kinetics of procalcitonin and C-reactive protein for early clinical stability in patients with bloodstream infections due to Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease, 2019, 93, 63-68.	1.8	11
276	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. International Journal of Antimicrobial Agents, 2019, 54, 442-448.	2.5	11
277	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Scoreâ€“Adjusted Analysis. Open Forum Infectious Diseases, 2019, 6, ofz251.	0.9	11
278	Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles. Microbial Pathogenesis, 2019, 128, 112-118.	2.9	11
279	La formaciÃ³n de grado en enfermedades infecciosas, resistencia y uso de antibiÃ³ticos desde la perspectiva de los estudiantes de Medicina. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 25-30.	0.5	11
280	Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 351-357.	6.0	11
281	Impact of KPC Production and High-Level Meropenem Resistance on All-Cause Mortality of Ventilator-Associated Pneumonia in Association with Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
282	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1837-1844.	2.9	11
283	Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. Open Forum Infectious Diseases, 2021, 8, ofab250.	0.9	11
284	Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. Frontiers in Immunology, 2022, 13, 860891.	4.8	11
285	Colonization by high-level aminoglycoside-resistant enterococci in intensive care unit patients: epidemiology and clinical relevance. Journal of Hospital Infection, 2005, 60, 353-359.	2.9	10
286	False extended-spectrum Â-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid. Journal of Antimicrobial Chemotherapy, 2007, 61, 301-308.	3.0	10
287	Pregnancy, obesity and other risk factors for complications in influenza A(H1N1) pdm09 infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 32-37.	0.5	10
288	Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. Future Microbiology, 2014, 9, 757-771.	2.0	10

#	Article	IF	Citations
289	Dalbavancin or Oritavancin for Skin Infections. New England Journal of Medicine, 2014, 371, 1160-1163.	27.0	10
290	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1020-1021.	9.1	10
291	Evaluation of the impact of a nationwide massive online open course on the appropriate use of antimicrobials. Journal of Antimicrobial Chemotherapy, 2018, 73, 2231-2235.	3.0	10
292	Efficacy of Î²â€lactam/Î²â€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€SOT Project). Transplant Infectious Disease, 2021, 23, e13520.	1.7	10
293	Bacteriemias por Acinetobacter baumannii: caracterÃsticas clÃnicas y pronÃ³sticas. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 242-247.	0.5	10
294	Doppler Transmitral Flow Pattern Is an Independent Prognostic Factor in Acute Myocardial Infarction. Cardiology, 1997, 88, 203-206.	1.4	9
295	Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 49-55.	0.5	9
296	EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol. BMJ Open, 2017, 7, e013634.	1.9	9
297	How should we best treat patients with bloodstream infections?. Future Microbiology, 2017, 12, 927-930.	2.0	9
298	Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project. Journal of Antimicrobial Chemotherapy, 2020, 75, ii2-ii19.	3.0	9
299	A comparative study between real-time PCR and loop-mediated isothermal amplification to detect carbapenemase and/or ESBL genes in Enterobacteriaceae directly from bronchoalveolar lavage fluid samples. Journal of Antimicrobial Chemotherapy, 2020, 75, 1453-1457.	3.0	9
300	Reporting methods of observational cohort studies in CMI. Clinical Microbiology and Infection, 2020, 26, 395-398.	6.0	9
301	Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study). International Journal of Antimicrobial Agents, 2021, 58, 106352.	2.5	9
302	Nosocomial Bacteremia Due to an As Yet Unclassified Acinetobacter Genomic Species 17-Like Strain. Journal of Clinical Microbiology, 2006, 44, 1587-1589.	3.9	8
303	Multidrug-resistant Acinetobacter baumannii: â€œEyes Wide Shutâ€?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2008, 26, 185-186.	0.5	8
304	A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. Journal of Microbiological Methods, 2010, 83, 307-311.	1.6	8
305	Control measures for Acinetobacter baumannii: a survey of Spanish hospitals. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 36-38.	0.5	8
306	Prognosis of 2009 A(H1N1) Influenza in Hospitalized Pregnant Women in a Context of Early Diagnosis and Antiviral Therapy. Antiviral Therapy, 2012, 17, 719-728.	1.0	8

#	Article	IF	Citations
307	Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. Clinical Microbiology and Infection, 2011, 17, 845-850.	6.0	8
308	Carbapenemase-producing Enterobacteriaceae: The end of the antibiotic era?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 1-3.	0.5	8
309	Risk factors, clinical presentation and prognosis of mixed candidaemia: a populationâ€based surveillance in Spain. Mycoses, 2016, 59, 636-643.	4.0	8
310	Clinical efficacy of Î²-lactam/Î²-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ Open, 2017, 7, e013268.	1.9	8
311	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
312	Therapy of Staphylococcus aureus bacteremia: Evidences and challenges. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 489-497.	0.5	8
313	Submissions and publications in corona times. Clinical Microbiology and Infection, 2020, 26, 803-804.	6.0	8
314	Impact of early interferon-Î² treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. Biomedicine and Pharmacotherapy, 2022, 146, 112572.	5.6	8
315	Prudent use of antibacterial agents: are we entering in an era of infections with no effective antibacterial agents? What can we do?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 577-579.	0.5	7
316	Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients. BMC Infectious Diseases, 2015, 15, 484.	2.9	7
317	Should we take into account ESBLs in empirical antibiotic treatment?. Intensive Care Medicine, 2016, 42, 2059-2062.	8.2	7
318	Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial. BMJ Open, 2017, 7, e015439.	1.9	7
319	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112.	1.3	7
320	Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol. BMJ Open, 2020, 10, e030608.	1.9	7
321	Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
322	Inappropriate use of ivermectin during the COVID-19 pandemic: Primum non nocere!. Clinical Microbiology and Infection, 2022, , .	6.0	7
323	Cytomegalovirus mononucleosis as a cause of prolonged fever and prominent weight loss in immunocompetent adults. Clinical Microbiology and Infection, 2004, 10, 468-470.	6.0	6
324	Sam68 is tyrosine phosphorylated and recruited to signalling in peripheral blood mononuclear cells from HIV infected patients. Clinical and Experimental Immunology, 2005, 141, 518-525.	2.6	6

#	Article	IF	Citations
325	Prudent use of antimicrobials: Have we done the best we can? The SEIMC and REIPI statement. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 485-486.	0.5	6
326	Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with Î²-lactams: a systematic review and meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1751-1758.	2.9	6
327	Genomic Evolution of Two Acinetobacter baumannii Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010). Genome Announcements, 2016, 4, .	0.8	6
328	How are trainees in clinical microbiology and infectious diseases supervised in Europe? An international cross-sectional questionnaire survey by the Trainee Association of ESCMID. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2381-2387.	2.9	6
329	Unsolicited consultation by infectious diseases specialist improves outcomes in patients with bloodstream infection: A prospective cohort study. Journal of Infection, 2018, 77, 503-508.	3.3	6
330	Development and validation of baseline, perioperative and at-discharge predictive models for postsurgical prosthetic joint infection. Clinical Microbiology and Infection, 2019, 25, 196-202.	6.0	6
331	Impact of infectious diseases consultation on the outcome of patients with bacteraemia. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611989357.	1.8	6
332	Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2020, 75, 2066-2075.	3.0	6
333	Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÃ‰): protocol for a randomised, pragmatic trial. BMJ Open, 2021, 11, e049481.	1.9	6
334	Prediction models in CMI. Clinical Microbiology and Infection, 2022, 28, 311-312.	6.0	6
335	Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study. Infectious Diseases and Therapy, 0, , .	4.0	6
336	Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 1-2.	0.5	5
337	Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort--authors' response. Journal of Antimicrobial Chemotherapy, 2014, 69, 3167-3168.	3.0	5
338	Duration of Colonization by Extended-Spectrum Î²-Lactamase-Producing Enterobacteriaceae in Healthy Newborns and Associated Risk Factors: A Prospective Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy312.	0.9	5
339	Incidence and Risk Factors for Acquisition of Extended-Spectrum Î²-Lactamase-Producing Enterobacteriaceae in Newborns in Seville, Spain: A Prospective Cohort Study. International Journal of Antimicrobial Agents, 2018, 52, 835-841.	2.5	5
340	Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains. Frontiers in Medicine, 2021, 8, 615540.	2.6	5
341	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. Clinical Microbiology and Infection, 2021, 27, 1746-1753.	6.0	5
342	Extendedâ€spectrum Î²â€lactamaseâ€producing and carbapenemâ€resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches. Transplant Infectious Disease, 2022, 24, .	1.7	5

#	Article	IF	Citations
343	Corynebacterium jeikeium osteomyelitis successfully treated with teicoplanin. Journal of Infection, 1997, 35, 325-326.	3.3	4
344	A comprehensive surveillance, control and management programme for Clostridium difficile infection. Journal of Hospital Infection, 2010, 74, 91-93.	2.9	4
345	New trends in infective endocarditis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 22-35.	0.5	4
346	Scientific evidence and research in antimicrobial stewardship. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 56-61.	0.5	4
347	Surveillance Systems from Public Health Institutions and Scientific Societies for Antimicrobial Resistance and Healthcare-Associated Infections in Europe (SUSPIRE): protocol for a systematic review. BMJ Open, 2017, 7, e014538.	1.9	4
348	Association between rectal colonisation by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae and mortality: a prospective, observational study. Journal of Global Antimicrobial Resistance, 2022, 29, 476-482.	2.2	4
349	Association between Timing of Colonization and Risk of Developing Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infection in Hospitalized Patients. Microbiology Spectrum, 2022, 10, e0197021.	3.0	4
350	Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: a multinational matched case-control study. Clinical Microbiology and Infection, 2022, 28, 1359-1366.	6.0	4
351	Similarities between the genetic environments of blaCTX-M-15 in Escherichia coli from clinical and food samples from Spain and overseas travellers. Journal of Antimicrobial Chemotherapy, 2011, 66, 2177-2177.	3.0	3
352	Uncoupling between core genome and virulome in extraintestinal pathogenic Escherichia coli. Canadian Journal of Microbiology, 2015, 61, 647-652.	1.7	3
353	Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study. Journal of Fungi (Basel, Switzerland), 2019, 5, 44.	3.5	3
354	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. Antibiotics, 2021, 10, 348.	3.7	3
355	Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	3
356	Higher prevalence of CTX-M-27-producing Escherichia coli belonging to ST131 clade C1 among residents of two long-term care facilities in Southern Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 335-338.	2.9	3
357	Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project. Microbiology Spectrum, 2022, 10, .	3.0	3
358	Daptomycin or Vancomycin for Methicillin-Resistant Staphylococcus aureus with a Vancomycin Minimum Inhibitory Concentration >1 Âg/L. Clinical Infectious Diseases, 2012, 54, 1375-1376.	5.8	2
359	Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study. BMC Research Notes, 2012, 5, 578.	1.4	2
360	Editorial. Therapeutic Advances in Infectious Disease, 2013, 1, 3-3.	1.8	2

#	Article	IF	Citations
361	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. Journal of Hepatology, 2018, 68, S44-S45.	3.7	2
362	An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. Clinical Infectious Diseases, 2021, 73, e4475-e4483.	5.8	2
363	Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis.. Antimicrobial Agents and Chemotherapy, 2021, 65, e0110221.	3.2	2
364	Evaluation of a Loop-Mediated Isothermal Amplification Assay to Detect Carbapenemases Directly From Bronchoalveolar Lavage Fluid Spiked With Acinetobacter spp.. Frontiers in Microbiology, 2020, 11, 597684.	3.5	2
365	A step forward in the definition of antimicrobial stewardship indicators: Better measurements, better work. Farmacia Hospitalaria, 2019, 43, 77-78.	0.6	2
366	Update on vascular catheter-related infections. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2007, 25, 37-46.	0.5	1
367	Fosfomycin Versus Meropenem In Bacteremic Urinary Tract Infections Caused By Extended-Spectrum Betalactamase Producing Escherichia Coli (Esbl-Ec): Forest Study. Clinical Therapeutics, 2015, 37, e34-e35.	2.5	1
368	In replyâ€"What Is the Optimal Timing for Surgical Treatment of Infective Endocarditis?. Mayo Clinic Proceedings, 2015, 90, 415-416.	3.0	1
369	Opportunities for antibiotic optimisation and outcome improvement in patients with negative blood cultures: study protocol for a cluster-randomised crossover trial, the NO-BACT study. BMJ Open, 2019, 9, e030062.	1.9	1
370	ESCMID white paper: a guide on ESCMID guidance documents. Clinical Microbiology and Infection, 2019, 25, 155-162.	6.0	1
371	Reply to â€œCMV merits further evolutionary and biological viewâ€• American Journal of Transplantation, 2020, 20, 1467-1468.	4.7	1
372	Role of inorganic phosphate concentrations in inÂvitro activity of fosfomycin. Clinical Microbiology and Infection, 2022, 28, 302.e1-302.e4.	6.0	1
373	Unneeded antibiotics for acute respiratory infections in primary care: stop as early as possible. Clinical Microbiology and Infection, 2021, , .	6.0	1
374	ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply. Clinical Microbiology and Infection, 2022, , .	6.0	1
375	Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Developmentâ€"Results from the PRO-BAC Cohort. Antibiotics, 2022, 11, 707.	3.7	1
376	Antimicrobial prophylaxis in surgery. Plastic and Reconstructive Surgery, 1987, 80, 329.	1.4	0
377	P1349 Risk factors for ciprofloxacin resistance among ESBL-producing Escherichia coli isolated from non-hospitalised patients in Spain. International Journal of Antimicrobial Agents, 2007, 29, S374.	2.5	0
378	P1652 Susceptibility of extended-spectrum Î²-lactamase-producing Escherichia coli strains causing nosocomially- and community-acquired bacteraemia. International Journal of Antimicrobial Agents, 2007, 29, S467.	2.5	0

#	Article	IF	Citations
379	Update on infections in ICU patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2008, 26, 39-48.	0.5	0
380	Evalutaion of two different control charts (I and U) in the study of mutiresistant bacteria contact precautions dynamics in a non-endemicity hospital setting. BMC Proceedings, 2011, 5, .	1.6	0
381	Treatment of Sepsis-Related Organ Dysfunction. JAMA - Journal of the American Medical Association, 2012, 308, 1205.	7.4	0
382	Reply to Fries et al and Valentin et al. Clinical Infectious Diseases, 2014, 58, 600-601.	5.8	0
383	Letter by Almendro-Delia et al Regarding Article, â€œAssociation Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditisâ€. Circulation, 2015, 132, e183.	1.6	0
384	AMS in an Era of Multidrug-Resistant Bacteria. , 2017, , 219-231.		0
385	Antimicrobial Stewardship in Spain. , 2017, , 317-319.		0
386	In Replyâ€"Statin Use Associated With a Decreased Risk of Community-Acquired Staphylococcus aureus Bacteremia. Mayo Clinic Proceedings, 2018, 93, 542.	3.0	0
387	â€˜Being a parent at ECCMID 2019â€™ â€“ ESCMID's reply. Clinical Microbiology and Infection, 2019, 25, 1161.	6.0	0
388	Reply to Woerther et al. Clinical Infectious Diseases, 2020, 71, 1129-1130.	5.8	0
389	How to limit bias in quasiexperimental studies. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 45-46.	0.3	0
390	CÃ³mo limitar los sesgos en estudios cuasiexperimentales. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 45-46.	0.5	0
391	Making treatment decisions in a void of information. Nature Medicine, 2021, 27, 575-575.	30.7	0
392	Delayed Tuberculin Reactivity in Indochinese Persons. Annals of Internal Medicine, 1997, 126, 661.	3.9	0
393	Introduction by JesÃºs RodrÃguez-BaÃ±o. , 2017, , xix.		0
394	Therapy of Staphylococcus aureus bacteremia: Evidences and challenges. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 489-497.	0.3	0
395	Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project. BMJ Open, 2020, 10, e035460.	1.9	0
396	Interplay between IncF plasmids and topoisomerase mutations conferring quinolone resistance in the Escherichia coli ST131 clone: stability and resistance evolution. European Journal of Clinical Microbiology and Infectious Diseases, 2021, , 1.	2.9	0

#	Article	IF	Citations
397	Leishmaniasis visceral y tuberculosis peritoneal en un paciente con infecciÃ³n por el virus de la inmunodeficiencia humana. Medicina ClÃnica, 2003, 121, 357-358.	0.6	0
398	Errata concerning Volume 14, Supplement 1, January 2008. Clinical Microbiology and Infection, 2008, 14, 293.	6.0	0